Endocrinology

True or false? Clinicians should use 2 growth hormone stimulation tests to diagnose patients suspected of idiopathic AGHD. Answer plus 5 more.

Adult growth hormone deficiency treatment is safe and effective, but who is tracking the social and economic impact, reviewers ask?

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

What is the classic triad of symptoms that can be considered pathognomonic for pheochromocytoma? Answer and 4 more questions in this short test.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

Authors of a new study have found that widespread use of ultrasound increases the diagnosis of low-risk thyroid cancers and may lead to harm following thyroid surgery. 

Using relevant clinical trial data, investigators created a price tag of about $6300 annually for the very effective, often costly inhibitor.

Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.

The updated staging system results in 36% of patients being reclassified to a lower stage, reducing overdiagnosis.

The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.

Ezetimibe 10 mg/day significantly reduced the incidence of atherosclerotic cardiovascular events in elderly patients with high LDL cholesterol compared to control.

In visits with overweight or obese children with high blood pressure, pediatricians either provide no communication about BP or unclear or dismissive statements, unless SBP is ≥120 mmHg.

Find out what you know about the facts and some emerging evidence.

The new score was developed by incorporating a weighted score into 6 clinical facgtors associated with AGHD.

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

Ronald Gentile, MD, and colleagues investigated pain-reduction strategies following intravitreal injections. The results have implications for patient experience, physician ratings, and treatment adherence.

Sample: Under which circumstances do the recent USPSTF guidelines recommend screening for thyroid dysfunction? 

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 months before requiring a refill.

My partner is leaving in December. She asked me not to be angry; not to hate her. I said I couldn't and wouldn't -- but to ask me again in January.

Which common treatment method for hyperthyroidism will lower a patient's risk for cardiovascular disease? Authors of a new study sought to find out.

New data suggest hepatitis C infection, but not hepatitis B infection, increases the prevalence of diabetes in patients who undergo kidney transplants.

A patient may resist the move to insulin in the face of even irrefutable evidence that it's time. A GLP-1 RA is often moe attractive. Why? Also, why not?

TRIM-AGHD was found in this study to be highly responsive to patient-reported response to treatment in adults naïve to GH therapy.

The once-weekly novel growth hormone derivative was favored over once-daily hGH in this head-to-head trial that evaluated treatment satisfaction.

A new study suggests it may be time to scrutinize the efficacy of the longstanding standard of care for hypothyroidism.

Can albiglutide reduce the risk of cardiovascular events in T2DM patients? A new study sheds some light.